Illustrative trajectory (toward the 72-week endpoint)
What to expect by phase
| Phase | Typical experience | What matters |
|---|---|---|
| Weeks 1-4 (2.5 mg) | Appetite drops; early scale changes | Starter dose — not therapeutic yet |
| Weeks 5-20 (titration) | Steady loss as dose rises every ~4 weeks | Manage side effects; do not rush |
| Weeks 20-48 | Continued, often fastest sustained loss | Consistency compounds results |
| Weeks 48-72 | Loss slows toward a plateau | Focus shifts to maintenance |
Why the titration schedule matters
Tirzepatide starts at 2.5 mg weekly and increases by 2.5 mg roughly every four weeks to a maximum tolerated dose (up to 15 mg). Early doses are mainly about tolerability, so judging results before you reach a therapeutic dose can mislead. See our dosing schedule for the full plan.
Early weeks: water, food weight, and fat
Some of the earliest scale movement reflects reduced food volume and water shifts rather than fat loss, which is normal and not a reason to judge the medication in week two. Real fat loss accumulates over the titration weeks as the dose climbs, which is why patience through the first months usually pays off more than early scale-watching.
Managing the plateau
As you approach a year to eighteen months, loss typically slows and settles — a plateau, not a failure. The goal then shifts from losing to maintaining, and clinicians often emphasize protein intake, resistance training to preserve muscle, sleep, and dose stability. If weight climbs meaningfully while still on treatment, discuss it rather than self-adjusting the dose.
Staying on track
Weight loss is rarely linear — expect faster and slower weeks. Track trends over months, not days. Pair the medication with protein-forward eating and activity, and keep clinician follow-ups. For per-dose expectations, see weight loss by dose; for tolerability, see our side-effects data.
Why progress is not a straight line
Weight can stall or briefly rise even when the medication is working, because of water retention, hormonal cycles, sodium, glycogen, and normal daily variation. A flat week or two is not evidence of failure. The trial data describe a smooth average curve, but any individual’s week-to-week chart is bumpy. The practical response is to weigh under consistent conditions, look at four-week trends rather than daily numbers, and resist the urge to change the plan based on short-term noise. If a genuine multi-month plateau arrives before your goals, that is a conversation to have with your clinician about dose, habits, or whether you have reached a healthy set point.
Frequently asked questions
When does tirzepatide start working?
Appetite changes often appear within the first week or two, and measurable weight loss typically begins within the first month, building over roughly 72 weeks.
When do results plateau?
In the SURMOUNT program, weight loss continued for about 72 weeks before tending to level off. The plateau point varies by person and dose.
Why is my weight loss slower than the averages?
Titration pace, dose reached, consistency, starting weight, and biology all affect speed. Trial averages reflect the maximum tolerated dose over a long period.
Will I regain weight if I stop?
Studies show weight tends to return after stopping, which is why obesity medicine is generally managed long-term under clinician guidance.
References
- Eli Lilly. Zepbound prescribing information (titration schedule).
- Jastreboff AM et al. SURMOUNT-1. NEJM, 2022.
- American College of Cardiology. Early weight-loss observations in SURMOUNT-5. 2025.